Novo
View company profile →
Greedy and lack of care of for people with diabetes
Withdrawal of the Ryzodeg 70/30 Flextouch pen has impacted people with diabetes in Australia. Their excuse? The mechanism of the Flextouch pen is in short supply, as it is shared with the Semaglutide devices. As the Flextouch is still widely available in the UK, India and US, I am smelling bull***. More likely they do not make as much money for it in Australia versus the US. I have patients that cannot use the Novopen due to dexterity issues, particularly post CVA and putting in that blasted cartridge. You only have to see their pricing racket with Wegovy and Ozempic to see how capital focused they are. Providers will remember, especially when your rivals bring out new products..... what goes around ......